UroGen develops and sells gel-based treatments for urinary tract cancers, including Jelmyto and Zusduri. URGN reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 6 | Guggenheim | Maintained | Buy | |
| Aug 6 | HC Wainwright & Co. | Maintained | Buy | |
| Aug 5 | TD Cowen | Maintained | Buy | |
| Jul 21 | Guggenheim | Maintained | Buy | |
| Jul 16 | Oppenheimer | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in URGN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether URGN is in one of them and how their past URGN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered URGN in an article yet. Here's the latest on the wider market.
About UroGen Pharma
UroGen is a biotechnology company based in Ra'Anana, Israel, that develops and sells treatments for urothelial cancers, which affect the lining of the urinary tract. Its products use a gel technology called RTGel, which turns from liquid to gel at body temperature so that a cancer drug can stay in the bladder or upper urinary tract for longer. Its approved products, Jelmyto and Zusduri, both contain the chemotherapy drug mitomycin, and the company is also developing an investigational oncolytic virus. Its customers are patients with these cancers and the doctors who treat them.
- Headquarters
- Ra'Anana, Israel